Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari, Lara Felicioni, Michela Buscarino et al. · Clinical Cancer Research · 2011
PURPOSE: KRAS mutations represent the main cause of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC). We evaluated whether highly sensitive methods for KRAS investigation improve the accuracy of predictions of anti-EGFR MoAbs efficacy. EXPERIMENTAL DESIGN: We retrospectively evaluated objective tumor responses in mCRC patients treated with cetuximab or panitumumab. KRAS codons 12 and 13 were examined by direct sequencing, MALDI-TOF MS, mutant-enriched PCR, and engineered mutant-enriched PCR, which have a sensitivity of 20%, 10%, 0.1%, and 0.1%, respectively. In addition, we analyzed KRAS codon 61, BRAF, and PIK3CA by direct sequencing and PTEN expression by immunohistochemistry. RESULTS: In total, 111 patients were considered. Direct sequencing revealed mutations in codons 12 and 13 of KRAS in 43/111 patients (39%) and BRAF mutations in 9/111 (8%), with almost all of these occurring in nonresponder patients. Using highly sensitive methods, we identified up to 13 additional KRAS mutations compared with direct sequencing, all occurring in nonresponders. By analyzing PIK3CA and PTEN, we found that of these 13 patients, 7 did not show any additional alteration in the PI3K pathway. CONCLUSIONS: The application of highly sensitive methods for the detection of KRAS mutations significantly improves the identification of mCRC patients resistant to anti-EGFR MoAbs.
Cited by 159 works. doi:10.1158/1078-0432.ccr-10-3137
Authors
- Francesca Molinari
- Lara Felicioni
- Michela Buscarino
- Sara De Dosso
- Fiamma Buttitta
- Sara Malatesta
- Alessandra Movilia
- Marco Luoni
- Renzo Luciano Boldorini
- Oscar Alabiso
- Salvatore Girlando
- Barbara Soini
- Alessandra Spitale
- Federica Di Nicolantonio
- Piercarlo Saletti
- Stefano Crippa
- Luca Mazzucchelli
- Antonio Marchetti
- Alberto Bardelli
- Milo Frattini
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- RAF/RAS oncogenes and mismatch-repair status
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- High-throughput oncogene mutation profiling in human cancer
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis